Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 4
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
Villanueva C, Torres F, Sarin SK, Shah HA, Tripathi D, Brujats A, Rodrigues SG, Bhardwaj A, Azam Z, Hayes PC, Jindal A, Abid S, Alvarado E, Bosch J; Carvedilol-IPD-MA-group and the Baveno Cooperation: an EASL Consortium. Villanueva C, et al. J Hepatol. 2022 Oct;77(4):1014-1025. doi: 10.1016/j.jhep.2022.05.021. Epub 2022 May 31. J Hepatol. 2022. PMID: 35661713 Free article.
Non-invasive tests for clinically significant portal hypertension after HCV cure.
Semmler G, Lens S, Meyer EL, Baiges A, Alvardo-Tapias E, Llop E, Tellez L, Schwabl P, Mauro E, Escudé L, Díez C, Ibañez-Samaniego L, Puente Á, Fortea JI, Abadía M, Zanetto A, Conthe A, Hernandez-Évole H, Luzko Scheid IS, Jia J, Yoshiji H, Francque SM, Tsochatzis EA, Russo FP, Crespo G, Forns X, Bañares R, Villanueva C, Hernández-Gea V, Reiberger T, Bosch J, García Pagán JC, Mandorfer M; A study by the Baveno Cooperation: an EASL consortium. Semmler G, et al. J Hepatol. 2022 Dec;77(6):1573-1585. doi: 10.1016/j.jhep.2022.08.025. Epub 2022 Sep 5. J Hepatol. 2022. PMID: 36063968 Free article.
Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event.
Balcar L, Tonon M, Semmler G, Calvino V, Hartl L, Incicco S, Jachs M, Bauer D, Hofer BS, Gambino CG, Accetta A, Brocca A, Trauner M, Mandorfer M, Piano S, Reiberger T; Baveno Cooperation: an EASL consortium. Balcar L, et al. JHEP Rep. 2022 Jun 3;4(8):100513. doi: 10.1016/j.jhepr.2022.100513. eCollection 2022 Aug. JHEP Rep. 2022. PMID: 35845294 Free PMC article.
Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding.
Balcar L, Mandorfer M, Hernández-Gea V, Procopet B, Meyer EL, Giráldez Á, Amitrano L, Villanueva C, Thabut D, Samaniego LI, Silva-Junior G, Martinez J, Genescà J, Bureau C, Trebicka J, Herrera EL, Laleman W, Palazón Azorín JM, Alonso JC, Gluud LL, Ferreira CN, Cañete N, Rodríguez M, Ferlitsch A, Mundi JL, Grønbæk H, Hernandez Guerra MN, Sassatelli R, Dell'Era A, Senzolo M, Abraldes JG, Romero-Gómez M, Zipprich A, Casas M, Masnou H, Primignani M, Krag A, Nevens F, Calleja JL, Jansen C, Catalina MV, Albillos A, Rudler M, Tapias EA, Guardascione MA, Tantau M, Schwarzer R, Reiberger T, Laursen SB, Lopez-Gomez M, Cachero A, Ferrarese A, Ripoll C, La Mura V, Bosch J, García-Pagán JC; International Variceal Bleeding Observational Study Group by the Baveno Cooperation: an EASL consortium. Balcar L, et al. J Hepatol. 2024 Jan;80(1):73-81. doi: 10.1016/j.jhep.2023.10.007. Epub 2023 Oct 16. J Hepatol. 2024. PMID: 37852414
Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease.
Kong Y, Lv T, Li M, Zhao L, Meng T, Wu S, Wei W, Zhang Q, Chen S, You H, Lens S, Yoshiji H, Francque S, Tsochatzis E, Sarin SK, Mandorfer M, Jia J; BAVENO Cooperation: an EASL consortium. Kong Y, et al. Hepatol Int. 2022 Oct;16(5):1052-1063. doi: 10.1007/s12072-022-10369-w. Epub 2022 Sep 9. Hepatol Int. 2022. PMID: 36083440
Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD.
Paternostro R, Kwanten WJ, Hofer BS, Semmler G, Bagdadi A, Luzko I, Hernández-Gea V, Graupera I, García-Pagán JC, Saltini D, Indulti F, Schepis F, Moga L, Rautou PE, Llop E, Téllez L, Albillos A, Fortea JI, Puente A, Tosetti G, Primignani M, Zipprich A, Vuille-Lessard E, Berzigotti A, Taru MG, Taru V, Procopet B, Jansen C, Praktiknjo M, Gu W, Trebicka J, Ibanez-Samaniego L, Bañares R, Rivera-Esteban J, Pericas JM, Genesca J, Alvarado E, Villanueva C, Larrue H, Bureau C, Laleman W, Ardevol A, Masnou H, Vanwolleghem T, Trauner M, Mandorfer M, Francque S, Reiberger T; a study by the Baveno Cooperation: an EASL consortium. Paternostro R, et al. J Hepatol. 2024 May 30:S0168-8278(24)00368-4. doi: 10.1016/j.jhep.2024.05.033. Online ahead of print. J Hepatol. 2024. PMID: 38823501 Free article.